A multicenter study of 638 cases of community-acquired pneumonia due to Streptococcus pneumoniae (SP-CAP) was performed to assess current levels of resistance. Of the pneumococcal strains, 35.7% had an minimum inhibitory concentration (MIC) of penicillin of у0.12 mg/mL (3 isolates had an MIC of 4 mg/mL), 23.8% had an MIC of erythromycin of 128 mg/mL, and 22.2% were multidrug resistant. Logistic regression determined that chronic pulmonary disease (odds ratio [OR], 1.44], human immunodeficiency virus infection (OR, 1.98), clinically suspected aspiration (OR, 2.12), and previous hospital admission (OR, 1.69) were related to decreased susceptibility to penicillin, and previous admission (OR, 1.89) and an MIC of penicillin of MIC у0.12 mg/mL (OR, 15.85) were related to erythromycin resistance (MIC, у1 mg/mL). The overall mortality rate was 14.4%. Disseminated intravascular coagulation, empyema, and bacteremia were significantly more frequent among patients with penicillin-susceptible SP-CAP. Among isolates with MICs of penicillin of у0.12 mg/mL, serotype 19 was predominant and was associated with a higher mortality rate. In summary, the rate of resistance to b-lactams and macrolides among S. pneumoniae that cause CAP remains high, but such resistance does not result in increased morbidity.
coming a problem throughout the world [1, 2] . Recent data from the Alexander Project show that there are high rates of penicillin resistance among S. pneumoniae in France and Spain, with intermediate and resistant strains currently accounting for ∼50% of isolates [3] [4] [5] [6] . S. pneumoniae strains that are resistant to penicillins also have decreased susceptibility to other antibiotics [7, 8] , which may limit the choice of available antimicrobials for empirical treatment of communityacquired pneumonia (CAP). Macrolide resistance among pneumococci is also increasing in Europe and in the United States and other countries [5, [9] [10] [11] .
Recognition of patients with an increased risk of acquiring drug-resistant pneumococcal pneumonia is essential for control of the epidemic spread of these strains and selection of appropriate initial antimicrobial treatment. Several risk factors for aquisition of penicillin-and multidrug-resistant pneumococci have been reported [12] [13] [14] [15] [16] , but the risk factors for acquisition of pneumonia caused by erythromycin-resistant S. pneumoniae have been studied less frequently [11, 17] . Moreover, the clinical impact of drug-resistant S. pneumoniae is controversial. All currently available studies suggest that the MIC of penicillin (р2 mg/mL) is not independently associated with an increased mortality rate, but an effect of resistance on morbidity is not so evident [18] [19] [20] [21] [22] [23] [24] [25] [26] . Therapeutic failures involving macrolides have been reported among patients who are infected with erythromycin-resistant pneumococci [27] . To better understand the epidemiological and clinical aspects of drug-resistant S. pneumoniae pneumonia, a prospective, multicenter study was conducted in Spain, a country with a high rate of multiple antimicrobial-resistant pneumococci.
PATIENTS, MATERIALS, AND METHODS
Design and study population. From January 1999 through April 2000, a multicenter, observational, prospective study was performed in 35 Spanish hospitals. All consecutive adult (age, 116 years) patients who received a diagnosis of pneumococcal CAP were included. A diagnosis of CAP was assumed in the presence of acute onset of signs and symptoms suggesting lower respiratory tract infection at hospital admission and radiographic evidence of a pulmonary infiltrate that neither was preexisting nor had another known cause.
Diagnostic criteria.
Microbial investigation techniques were ordered at the discretion of the attending physician. A diagnosis of probable pneumococcal pneumonia was made in cases in which there was a predominance of gram-positive cocci in pairs and chains and heavy growth of S. pneumoniae on validated sputum and/or tracheobronchial aspirate (BAS) cultures. A definite diagnosis of pneumococcal pneumonia was considered when (1) there was a diagnosis of probable pneumococcal pneumonia and a urinary antigen test result was positive for S. pneumoniae, or (2) one of the following criteria were met: (a) у1 blood culture was positive for S. pneumoniae; (b) pleural fluid, transthoracic needle aspiration, or lung biopsy specimens yielded S. pneumoniae; or (c) there was bacterial growth of у10 3 cfu/mL of S. pneumoniae with a protected specimen brush and/or у10 4 cfu/mL with a bronchoalveolar lavage specimen. Mixed infections were diagnosed when another likely microorganism was identified and у1 of the following criteria were met: (1) there was a у4-fold increase in IgG titers for Chlamydia pneumoniae, Chlamydia psittaci, Legionella pneumophila, Coxiella burnetii, or respiratory viruses; (2) there was a single elevated IgM titer for Mycoplasma pneumoniae; (3) a urinary antigen test was positive for Legionella pneumophila; (4) another bacterial pathogen was identified (in accordance with standard methods) in samples other than sputum or BAS samples.
Data collection. Baseline data on patient demographic characteristics and clinical and laboratory findings were collected by clinical research using a standardized data collection form. The presence or absence of the following conditions and characteristics was assessed: residence, smoking, alcohol or illicit drug abuse, chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, cardiovascular diseases, diabetes mellitus, solid or hematologic malignancy, chronic renal or hepatic disease, neurologic disease, suspicion of aspiration, swallowing dysfunction, previous use of b-lactams (for у5 days in the past 3 months), use of glucocorticosteroids or immunosuppressive drugs, HIV infection, immunologic disease, splenectomy, prior pneumonia, and hospitalization within the previous 3 months. All laboratory tests were performed using conventional equipment. The included samples were obtained from the patient in the emergency department. Complications that occurred р30 days after presentation with CAP were recorded; these consisted of worsening of any major underlying disease and/or presence of shock (blood pressure of р90 mm Hg that was not corrected by administration of intravenous fluids or for which pressor medication was required), disseminated intravascular coagulation (DIC), renal insufficiency (serum creatinine level of 11.5 mg/dL and/or blood urea nitrogen level of 120 mg/dL in patients with previously normal function), respiratory failure (partial pressure of oxygen/fraction of inspired oxygen of !300 mm Hg or of !200 mm Hg in patients with COPD), and extrapulmonary involvement of pneumococcal pneumonia. The need for hospital admission, Pneumonia Severity Index (PSI) score [28] , transfer to the intensive care unit or receipt of mechanical ventilation, and mortality at 30 days after presentation were assessed for all patients. Duration of antibiotic therapy (oral and intravenous) was also evaluated. Thirty days after the diagnosis of CAP, patients were asked about the presence of respiratory symptoms, and a new chest radiograph was obtained.
Antimicrobial susceptibility testing. Antibiotic susceptibility tests were done during routine patient care at each institution. All pneumococcal isolates were subcultured, stored frozen at Ϫ70ЊC, and subsequently submitted to the National Center of Microbiology (Majadahonda, Madrid) for serotyping [6, 29] and antimicrobial susceptibility testing. Susceptibility or resistance of pneumococci to antimicrobials was assessed by dilution in agar, in accordance with the recommendations of the 2002 NCCLS guidelines [30] . The following antibiotics were tested: penicillin, amoxicillin, cefuroxime, cefotaxime, imipenem, vancomycin, teicoplanin, erythromycin, tetracycline, chloramphenicol, levofloxacin, and trovafloxacin. Clarithromycin and azithromycin were considered to be the same as erythromycin with regard to susceptibility and resistance. Ceftriaxone and cefotaxime were also considered to be equivalent. Multidrug resistance was defined as intermediate resistance or Other variables' definitions. Smokers were considered to be current smokers even if they had quit smoking р6 months before the beginning of the study. Alcohol abuse was established as an estimated daily consumption of у80 g of alcohol for at least the preceding year. Chronic pulmonary disease included COPD, chronic bronchitis, bronchiectasis, and chronic pulmonary conditions other than asthma. Immunosuppressive treatment was defined as the administration of any cytotoxic agent or corticosteroids (at dosages of у15 mg q.d. for prednisone) during the previous 6 months. A "typical clinical syndrome" was defined as presence of у3 of the following symptoms: cough, expectoration, pleuritic pain, fever, and onset or increase of dyspnea.
Statistical analysis. Results are expressed as . mean ‫ע‬ SD Continuous variables were compared using Student's t test; categorical variables were compared using Fisher's exact test and the x 2 test (with Yates' correction, when necessary). The association between serotypes and mortality was performed in accordance with the method described by Freeman [31] and Martín Andrés and Luna del Castillo [32] . To define which variables were significantly and independently associated with resistance, regression logistic analyses that tested several models were performed. Significance was defined as ; 95% CIs P ! .05 were based on the estimated variance of the regression coefficients. The choice of models was performed on the basis of the criteria defined by Hommer and Lemeshow [33] .
RESULTS

Patient characteristics.
There were a total of 638 patients (413 of whom were men), with a mean age of 61.5 years (range, 16-97 years). The main demographic characteristics, comorbidities, clinical symptoms, radiographic patterns, and PSI scores [28] are summarized in table 1. A definite diagnosis of pneumococcal CAP was noted for 466 patients (73%). A total of 459 (71.9%) of the S. pneumoniae isolates were recovered from blood and pleural fluid specimens. Serological samples were obtained from 340 patients (53.3%; single samples for 147 patients and paired samples for 193 patients). IgM titers for M. pneumoniae were determined for 109 patients. One hundred sixty urine samples were analyzed for Legionella antigen. Mixed infections were present in 34 patients (5.3%). There were 28 double infections and 6 triple infections.
Antimicrobial susceptibilities. The in vitro activities of 12 antimicrobial agents against 638 S. pneumoniae isolates (1 strain per patient) are shown in table 2. Sixty-five of the 638 patients were infected with penicillin-resistant pneumococcus (the MIC was 2 mg/mL in 62 [9.7%] of 638 cases [95% CI, 7.53%-12.3% and 4 mg/mL in 3 [0.5%] cases [95% CI, 0.09%-1.37%). Penicillin-nonsusceptible strains (MIC, у0.12 mg/mL) were more frequently recovered from patients classified as having probable pneumococcal pneumonia (x 2 , 25.71; ) than among P ! .00001 those who were not. Sixty-six specimens recovered from the upper respiratory tract (i.e., sputum samples; 50%), 34 samples recovered from the lower respiratory tract (i.e., BAS, protected specimen brush, transthoracic needle aspiration, and bronchoalveolar lavage samples; 54.8%), and 129 invasive isolates (i.e., blood and pleural fluid samples; 29.1%) had intermediate or high-level resistance to penicillin (x 2 , 30.11; ). P p .0000 Overall, cefotaxime and amoxicillin were the most active blactam agents. One hundred seventy-four strains (27.4%) were characterized as being erythromycin nonsusceptible (MIC, у1 mg/mL). Four strains had an MIC of 2 mg/mL, 2 had an MIC of 8 mg/mL, 3 had an MIC of 16 mg/mL, 7 had an MIC of 32 mg/mL, and 6 had an MIC of 64 mg/mL. The MIC of erythromycin was 128 mg/mL for 152 pneumococcal isolates (23.8%; 95% CI, 20.5%-27.1%). Again, isolates recovered from blood specimens exhibited a lower rate of erythromycin resistance than did isolates recovered from the respiratory tract. The MIC for the 4 levofloxacin-resistant isolates (0.62%; 95% CI, 0.17%-1.6%) was 16 mg/mL, and all of these isolates were multidrug resistant. Only 27 (4.2%; 95% CI, 2.81%-6.1%) of the levofloxacin-susceptible strains had an MIC of 2 mg/mL. Of this collection of pneumococcal isolates, 142 (22.2%) of 638 were found to be resistant to multiple drugs. Cross-resistance data are shown in tables 3 and 4).
Penicillin-nonsusceptible SP-CAP was more likely to be diagnosed in patients with chronic pulmonary diseases (OR, ) and an MIC P p .031 of penicillin of у0.12 mg/mL (OR, 15.85; 95% CI, 10.16-24.72) were also related with erythromycin-resistant pneumococcus (tables 5 and 6).
Serotypes. Frequency, nonsusceptibility to penicillin, and associated mortality for different serotypes are shown in figure 1. Among the 36 different serotypes identified in our series, the most common, accounting for 35% of the total, were serotypes 3 (16.9%), 19 isolates) was 17%, and it was 28% among patients infected with a serotype 19 pneumococcal isolate ( ). P р .05 Prognoses and outcomes for patients. Ninety-three percent of the patients were initially admitted to the hospital (95% CI, 90.8%-94.9%). Outcomes and complications (according to the susceptibility of the isolated pneumococcal strains) are shown in tables 7 and 8. We could not demonstrate any effect of antimicrobial resistance on morbidity and mortality. Only patients with DIC, empyema, or bacteremia were significantly more likely to be infected with penicillin-susceptible S. pneumoniae. Bacteremia was also significantly more common among patients infected with erythromycin-susceptible pneumococci. 
DISCUSSION
The most important findings of this study are the following: (1) patients with chronic pulmonary disease, HIV infection, or suspected aspiration or who were admitted to the hospital within the previous 3 months were more likely than other patients to have penicillin-resistant pneumococcal pneumonia; (2) previous hospital admissions and decreased susceptibility to penicillin were independent risk factors for erythromycin resistance; (3) DIC, empyema, and bacteremia were significantly more common in patients with drug-susceptible pneumococcal CAP; (4) among pneumococcal-resistant isolates, serotype 19 was predominant, and this serotype was associated with a significantly higher mortality rate than were other serotypes.
In our study, the overall national rate of penicillin resistance among clinical isolates of S. pneumoniae was 35.7%. These findings confirm the most recent published results from Spain [4] [5] [6] 12] and from the United States [34] . With regard to highlevel resistance to penicillin, our series found that the prevalence had apparently decreased to 10.2%, compared with the findings of recent surveys [5] . Of 638 isolates, only 3 had an MIC of 4 mg/mL, and there were no isolates with an MIC of у8 mg/mL. Antimicrobial resistance rates are highest among isolates recovered from respiratory specimens and from children; in our study, only adult patients with CAP were included, and 60.2% of isolates were recovered from blood and pleural fluid samples, which may explain these lower rates of high-level pneumococcal penicillin-resistance. Rates of resistance to all b-lactam agents increased in parallel with rates of penicillin resistance, and amoxicillin and cefotaxime nonsusceptibility clustered only in penicillin-resistant S. pneumoniae. It is important to note that amoxicillin now has higher breakpoints (susceptible, р2 mg/ mL; intermediate, 4 mg/mL; resistant, у8 mg/mL [30] ) than before, which may give the impression that it is more active in vitro than are other antibiotics for which the breakpoints have not been changed. Twenty-four percent of isolates in our series had an MIC of erythromycin of 128 mg/mL. This implies that ermB-mediated ribosomal methylation is the predominant macrolide resistance mechanism in this study, whereas most of the erythromycin-resistant pneumococcal isolates in the United States display the efflux phenotype [34] .
Relatively high rates of ciprofloxacin resistance in S. pneumoniae have been reported recently in Spain, mainly clustered in erythromycin-and penicillin-nonsusceptible strains [5, 35, 36] . Although ciprofloxacin resistance is not a good marker for resistance to newer quinolones, it could be a warning signal for a future increase. Levofloxacin was introduced in Spain in September 1998, which can explain the current low rates of resistance [37, 38] . In our study, 4 strains of S. pneumoniae had an MIC of levofloxacin of 16 mg/mL and also showed resistance to 4-5 additional antimicrobials. Multidrug resistance continues to grow as a problem among strains of S. pneumoniae. Overall, 22.2% of the pneumococcal isolates tested in this study were resistant to у3 different classes of antimicrobials, and 58.4% of these isolates were resistant to у4 different antimicrobial classes. Increases in the frequency of resistance to other antimicrobials occurred exclusively among penicillin-resistant isolates. Among the multidrug-resistant isolates in our study, the predominant serotype was 19 (28.9%), suggesting a strong clonal relationship.
In this study, chronic pulmonary disease, HIV infection, suspected aspiration, and previous hospital admissions were each independent predictors of penicillin-resistant pneumococcal pneumonia. In contrast with the most recent recommendations of the American Thoracic Society [2] , age, alcoholism, and previous or concomitant therapy with b-lactams or corticosteroids were not found to be significantly associated with penicillin resistance. The limited number of patients who had previously received therapy with b-lactams (9.7%) or immunosuppressive therapy (9.6%) in our series might preclude their identification as potential risk factors for drugresistant pneumococci. In addition, a longer interval for assessing prior exposure to b-lactams should have been considered [39] . There was a trend for older age (165 years) and PSI score to be associated with penicillin-resistant SP-CAP (P p ); however, we are uncertain whether the presence of com-.057 orbidities, rather than age, is the determining condition that predisposed to this etiology in CAP. In fact, only patients in class V were significantly associated with penicillin-resistant pneumococcal pneumonia. Furthermore, the effect of age as a risk factor has recently been reported to be less clear [8] . Pulmonary comorbidity and HIV infection predisposed patients to pneumonia caused by penicillin-resistant S pneumoniae. This is not unexpected, considering that such patients are more likely to be hospitalized and to receive antibiotics-factors that have repeatedly been associated with penicillin-resistant pneumococci [14] . COPD was identified as a major risk factor for acquisition of multidrug-resistant S. pneumoniae during an outbreak of nosocomial infection in The Netherlands [40] , probably because the spread of pneumococci is biased toward the most vulnerable patients. Ho et al. [41] also reported that patients with COPD could be an important reservoir for levofloxacin-resistant pneumococci. Resistance to erythromycin has increased almost in parallel with resistance to penicillin.
Hospitalization during the previous 3 months was also independently associated with erythromycin-resistant SP-CAP. These findings could be related to the increase in use of antimicrobials and, particularly, of the newer long-acting macrolides [11] . It should be noted that, although there is a clear association between antimicrobial exposure and selection of resistance, antibiotics vary in their ability to select resistant mutants, and macrolides more efficiently induce the emergence of resistant subpopulations than do aminopenicillins [41] . Considering the in vitro rate of macrolide resistance among pneu- mococci and the median MIC of erythromycin in our study, empirical treatment of CAP with an orally administered macrolide should be reserved for younger and healthier patients with no high-risk factors for drug-resistant S. pneumoniae [42] . The impact of drug-resistant S. pneumoniae on morbidity and mortality is still controversial. In our study, DIC, empyema, and bacteremia were more frequent among patients infected with a penicillin-susceptible pneumococcus, which may reflect the biological cost that resistance-determining mutations engender on the fitness of bacteria. However, differences are small and seem unlikely to be clinically significant-that is, they will not affect the choice of antibiotics, because many drug-resistant strains cause bacteremia. This is also true for erythromycin susceptibility. In our series, the mortality rate was higher among patients with strains that were intermediately or highly resistant to penicillin (18.3% and 18.5%, respectively) than among patients with penicillin-susceptible isolates (12.2%), but the differences were not significant ( ). This trend may have P p .054 been statistically significant if more patients had been studied. When deaths during the first 4 hospital days were excluded, Feikin et al. [21] found that mortality was significantly associated with an MIC of penicillin of у4 mg/mL and an MIC of cefotaxime of у2 mg/mL. These data suggest that high-level resistance may be associated with adverse outcome. In our study, only 3 patients (0.5%) had CAP caused by S. pneumoniae with an MIC of penicillin of 4 mg/mL, and 2 of these patients died. Current levels of resistance to penicillin mostly do not surpass an MIC of 2 mg/mL, and serum and pulmonary levels achieved with b-lactams are several times higher than these MICs. As a consequence, and considering the oversensitive current definition of resistance, only a few patients with penicillinresistant SP-CAP receive truly discordant antimicrobial treatment, and most studies, including ours, are underpowered to establish the real impact on outcome of these resistant strains. The serotypes included in the 23-valent vaccine accounted for 88% of resistant strains in our study. According to our data, among pneumococcal-resistant isolates, serotype 19 was predominant, and is also associated with a significantly higher mortality rate in comparison with other serotypes. This may only reflect that serotype 19 was found in a high enough number of patients with sufficient lethality to produce significance when compared with the rest of the serotypes. However, certain serotypes seem to be prone to produce severe disease, and high case-fatality rates have been observed for infections caused by serotypes 3, 6B, and 19F in other studies. Some authors have suggested that serotype may play a more important role than antibiotic susceptibility in mortality due to infection with a pneumococcus [43, 44] .
